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1. SUMMARY 
For the time being bacterial resistance has become one of the most important problems for 
public health. A large number of microorganisms have been developed, by natural selection, 
random mutations that have caused many of the antibiotics used previously are no longer 
effective. Therefore there is an urgent need for new drugs which can control these resistant 
bacteria.  
Some cyclopeptides as polymyxin B and E (colistin) show good antibacterial activity against 
gram-negative resistant microorganisms. Even so, its administration is limited due to they can 
cause neuro and nephrotoxicity. 
In the present work the synthesis of three polymyxin analogs has been carried out, with the 
aim of improving the pharmacological activity of this cyclopeptide in gram-positive and negative 
bacteria, and additionally to reduce its toxicity when being administered.  
The analogs synthesis has been carried out by the solid phase peptide synthesis and the 
Fmoc/tBu strategy as amino acids protecting groups, and its cyclization has made by oxidation 
between two cysteine residues, forming a disulfide bond. The peptides obtained with high purity 
have been characterized by HPLC and ESI mass spectrometry. 
Moreover, the antibiotic activity of the synthesized analogs has been determined through its 
minimal inhibitory concentration (MIC). We obtained good results and good selectivity against 
gram-negative bacteria (0.25 – 2 μg/ml) and better activity than polymyxin against gram-positive 
bacteria. 
 
Keywords: peptide antibiotics, chemical synthesis, solid phase, microbiological activity  
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2. RESUM 
Actualment la resistència bacteriana s’ha convertit en un dels problemes més importants 
per a la salut pública. Un gran nombre de microorganismes ha desenvolupat, per selecció 
natural, mutacions a l’atzar que han provocat que molts dels antibiòtics utilitzats anteriorment ja 
no siguin efectius. Per aquest motiu hi ha una gran necessitat de desenvolupament de nous 
fàrmacs que puguin combatre aquests bacteris resistents. 
Els ciclopèptids com la polimixina B i E (colistina) presenten una bona activitat 
antibacteriana contra microorganismes resistents gramnegatius. Tot i això, la seva 
administració es veu limitada per la neuro i nefrotoxicitat que provoquen. 
En aquest treball s’ha dut a terme la síntesi de tres anàlegs de la polimixina amb l’objectiu 
de millorar l’efectivitat farmacològica d’aquest ciclopèptid, tant en bacteris grampositius com 
gramnegatius, i de reduir la toxicitat que presenta en ser administrat. 
La síntesi dels anàlegs s’ha dut a terme mitjançant la síntesi de pèptids en fase sòlida i 
l’estratègia de Fmoc/tBu com a grups protectors dels aminoàcids, i la seva ciclació s’ha realitzat 
per oxidació entre dos residus de cisteïna, formant un pont disulfur. Els pèptids obtinguts amb 
alta puresa s’han caracteritzat per HPLC i espectrometria de masses (ESI). 
A més, s’ha determinat l’activitat antibiòtica dels anàlegs sintetitzats mitjançant la seva 
concentració mínima inhibitòria (CMI). S’ha obtingut bons resultats, amb bones selectivitats 
enfront bacteris gramnegatius (0.25 – 2 μg/ml) i millor eficàcia que la polimixina contra bacteris 
grampositius. 
 
Paraules clau: pèptids antibiòtics, síntesi química, fase sòlida, activitat microbiològica 
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3. INTRODUCTION 
In recent years, the effectiveness of some antibiotics is gradually decreasing due to the 
emergence of multidrug resistance bacteria. Many of the antibiotic currently used act by 
mechanisms capable of developing resistance. This means that bacteria which were sensitive to 
the antibiotic, experience mostly irreversible changes and become resistant. Levels of 
resistance had been increasing at an alarming rate, so this has become a serious problem for 
public health, therefore there is an urgent need for new antibiotics to overcome this problem 
[1,2]. 
3.1. PEPTIDES AS ANTIBIOTICS 
Peptides are usually considered poor therapeutic candidates due to many factors, including 
their low oral bioavailability, the fact that they are easily removed from the circulatory system 
and its low ability to cross the physiological membranes. However, in last years pharmaceutical 
companies have increased their interest in peptides as potential therapeutic candidates 
because of their high effectiveness, which compensates the mentioned drawbacks [3,4]. 
3.1.1. Laboratory synthesis (SPPS) 
A peptide is a chain of amino acids linked together by amide bonds. Peptides are 
synthesized rapidly within living cells, but until recently could only be artificially synthesized in 
very long, slow processes that had poor yields and gave impure products [5,6]. In 1969 Bruce 
Merrifield described a new method for peptide synthesis, known as solid phase peptide 
synthesis (SPPS). This technique results in high yields of pure products and works more quickly 
than classical synthesis [7], and is based on attaching the first AA to a water-insoluble polymer 
and on protecting the reactive groups of the other AA following an orthogonal scheme, in order 
to ensure the only formation of the desired peptide. 
The general process for synthesizing peptides on a resin starts by attaching the first amino 
acid, the C-terminal residue, to the resin. To prevent the polymerization of the amino acid, the 
alpha amino group and the reactive side chains are protected with a temporary protecting 
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group. Then the resin is filtered and washed to remove byproducts and excess reagents. Next, 
the N-alpha protecting group is removed in a deprotection process and the resin is again 
washed to remove byproducts and excess reagents. Then the next amino acid is coupled to the 
attached amino acid. This is followed by another washing procedure, which leaves the resin-
peptide ready for the next coupling cycle. The cycle is repeated until the peptide sequence is 
complete. Then typically, all the protecting groups are removed, the peptide resin is washed, 
and the peptide is cleaved from the resin [8]. 
Figure 1. General SPPS cycle. 
The side chains of many AA are reactive and may form side products if left unprotected. For 
successful peptide synthesis, these side chains must remain protected despite repeated 
exposure to N-alpha deprotection conditions. Ideally, the N-alpha protecting group and the side 
chain protecting groups should be removable under completely different conditions, such as 
basic conditions to remove the N-alpha protection and acidic conditions to remove the side 
chain protection. This scheme is called ―orthogonal‖ protection [8]. 
3.1.2. Uses of synthetic peptides 
Synthetic peptides have two main uses: as peptide drugs and as peptides for diagnostic 
purposes [5,9]: 
 Peptide drugs are either naturally-occurring peptides or altered natural peptides. 
Many natural-occurring peptides are biologically active, such as polymyxins or 
some ADEPs. But in addition, the amino acids of an active peptide can be altered 
to make analogs of the original peptide. If the analog is more biochemically active 
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than the original peptide it is known as an agonist, and if it has the reverse effect 
is known as an antagonist. 
 Peptides can be designed that change color under certain conditions, and these 
can be used for diagnostic purposes. 
Antimicrobial peptides (AMPs) such as polymyxins provide a possible solution to the 
problem of bacterial resistance to conventional antibiotics. AMPs are a class of antibiotics that 
rarely spur the development of resistant microorganisms, because their main target is the lipid 
bilayer and their mechanism of action relies on ionic and hydrophobic interactions between this 
membrane (rich in anionic phospholipids) and the cationic character of most AMPs [10]. 
3.2. POLYMYXINS 
As explained earlier, there is an urgent need for new antibiotics to overcome the problem of 
the resistance, particularly those active against gram-negative bacteria, such as P. aeruginosa. 
Therefore, polymyxins are increasingly being used as last-time therapy to treat infections 
caused by this kind of bacteria [11]. 
3.2.1. General aspects 
Polymyxins are antimicrobial lipopeptides that were discovered more than 50 years ago. 
Polymyxin B (PxB) is a secondary metabolite produced by the bacterium Bacillus polymyxa 
(which is a gram-positive bacterium), with selectivity against gram-negative bacteria. These 
cationic peptides are mostly being used as last-resort antibiotics for otherwise untreatable 
serious infections, due to they can cause effects of neurotoxicity and nephrotoxicity. But even 
so, as explained above, PxB has an amphipathic nature and a cationic character (with five 
positive charges due to the amino acid Dab) that rarely cause the development of resistant 
bacteria [11,12]. 
So in view of the generally good antimicrobial activity of PxB and the low prevalence of 
resistance that exists, it is not surprising that there has been interest to design new polymyxin 
analogs which improve the microbiological, pharmacological and toxicological profiles of PxB 
[11]. 
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3.2.2. Structure 
The general structure of polymyxin B comprises a cyclic heptapeptide (with three positive 
charges due to the amino acid Dab) bound to a linear tripeptide, with two positive charges due 
to the same AA. As shows figure 2, the γ-amino group of 4-Dab is linked by an amide bond to 
the C-terminus of 10-Thr, while its α-amino group is connected to 3-Dab of the linar tripeptide. 
The α-amino group of 1-Dab is acylated with a hydrophobic chain (different for PxB1 and PxB2) 
[13]. 
Figure 2. Chemical structure of PxB, where the functional segments are colored as follows: fatty acid 
chain (red) which is formed by (S)-6-methyloctanoic acid in polymyxin B1 and by 6-methylheptanoic acid in 
polymyxin B2; linear tripeptide segment (green); heptapeptide (pink); hydrophobic motif in the ring (blue). 
The presence of positively charged residues, as well as the amphiphilic nature of PxB are 
crucial for its activity against gram-negative bacteria. These properties make polymyxins good 
candidates as antibiotics for therapeutic purposes. However, the severe toxicity to humans has 
limited their clinical use. This hurdle might be cleared by the development of non-toxic 
analogues [13]. 
4. OBJECTIVES 
The main objectives of this present work are: 
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 Protection of the amino acid H-(D)-Cys-OH with the groups p-Npys and Boc in 
order to find a good synthesis strategy for obtaining the compound Boc-(D)-Cys(p-
Npys)-OH. 
 Synthesis of three polymyxin analogs to obtain new antibacterial agents. These 
bioactive peptides have to improve the activity of polymyxin. The Fmoc/tBu solid 
phase peptide synthesis (SPPS) will be used for this purpose. 
 Purification and characterization of the peptides obtained by HPLC and ESI mass 
spectrometry. 
 Evaluation of the antimicrobial activity of the synthesized analogs with MIC test, in 
gram-positive and gram-negative bacteria. 
5. EXPERIMENTAL SECTION 
5.1. MATERIALS AND METHODS 
5.1.1. Solvents, reagents and products 
5.1.1.1. Solvents 
Acetic acid Pure quality, 99% Sigma-Aldrich 
AcOEt Synthesis quality Scharlau 
Acetone Synthesis quality Scharlau 
ACN HPLC quality Fischer 
CHCl3 Synthesis quality Scharlau 
DCM Synthesis quality Scharlau 
DMF* Synthesis quality SDS 
EtOH 99.5% quality Panreac 
Et2O* Synthesis quality Scharlau 
H2O* Milli-Q  
MeOH HPLC quality VWR 
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* The anhydrous DMF is prepared over molecular sieve and passed nitrogen stream before its use. 
* The dried Et2O is kept over Na. 
* The deionised water is filtered with a Milli-Q Plus (Millipore) system. 
5.1.1.2. Reagents 
Resin, RL and amino acids  
Bachem 
Iris Biotech 
Novabiochem 
PolyPeptide 
Fischer Scientific 
DIC Pure quality, 99% Sigma-Aldrich 
DIEA Quality Reagent Plus ®, 99% Sigma-Aldrich 
DMSO Synthesis quality Acros Organics 
DTNP Synthesis quality Merck 
HCl Aqueous 37% Scharlau 
Hexanoic acid Quality 99.0% Aldrich 
HOBt Pure quality, 99.0% Fluka 
MgSO4 anhydrous  Jescuder 
Na2CO3  Jescuder 
Ninhydrin Pure quality Koch-Light 
Octanoic acid Quality ≥ 98.0% Aldrich 
Piperidine Quality Reagent Plus ®, 99% Sigma-Aldrich 
TFA Quality Reagent Plus ®, 99% Sigma-Aldrich 
TIS  Sigma-Aldrich 
5.1.1.3. Products for biological assays  
Mueller Hinton-Broth (MHB) Oxoid 
PxB Sigma-Aldrich 
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5.1.2. General instrumentation 
Autoclave AUTESTER-E 
Centrifuge Hettich ROTOFIX 32 A 
Liquid chromatography Specified in section 5.4.1. 
Lyophiliser 
Virtis sentry 2.0. Freezemobile 
25EL 
Mass spectrometry Specified in section 5.4.2. 
pH measurement Strips with colour scale, Panreac 
Polyethylene filter Applied Separations 
Quartz cuvette Helma Analytics 
Rotary evaporator Heidoph Laborota 4000 
Sonicator Selecta MEDI-II 
Spectrophotometer Shimadzu UV-2401 PC 
Syringes Terumo 
Thin layer chromatography Merck 
5.1.3. Analytic methods 
5.1.3.1. Ninhydrin test (Kaiser test) 
It is a very sensitive test for primary amines, usually used in solid phase peptide synthesis to 
determinate if coupling reactions are complete. Ninhydrin reacts with free or deprotected amines 
producing an intense blue color (positive essay). 
As shows figure 3, ninhydrin (1, which is a yellow compound) reacts with a primary amine 
of an amino acid (2) forming an imine (3), in a nucleophilic addition-elimination and reversible 
reaction. This is followed by a descarboxylation reaction, and after that the imine 5 reacts with 
H2O in a hydrolysis reaction to form an aldehyde and a free amine again (6). Compound 6 
reacts with another equivalent of ninhydrin forming 7 and finally 8, which is the blue compound 
[7]. 
To perform the test two solutions are required: 
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 Reagent A: a solution with phenol (40 g) in absolute EtOH (10 ml) is prepared in 
hot. Following, 100 ml of destilled pyridine are added to 2 ml of a solution with 
KCN (65 mg) in H2O (100 ml). These two solutions are stirred separately with 4 g 
of Amberlite MB-3 resin for 45 minutes. Then, are filtered and the filtrates are 
mixed. 
 Reagent B: a solution of ninhydrin (2.5 g) in absolute EtOH (50 ml) is prepared. 
This solution must be protected from light. 
Figure 3. Reaction mechanism of ninhydrin test. 
To carry out the essay, a little sample of peptide-resin (washed with DCM and dried with a 
vacuum pump) is introduced in a small test tube. Six drops of reagent A and two drops of 
reagent B are added. The tube is heated at 110ºC for 3 minutes. 
After that, the solution remains yellow (negative assay) if no free primary amines are 
present. This means the coupling reaction is completed at least 99.5%. Contrary, the solution 
turns dark blue when primary amine is present (positive assay), so a recoupling step will be 
necessary. 
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5.1.3.2. Thin layer chromatography 
Thin layer chromatography is performed on aluminium sheets which are coated with a thin 
layer of silica gel. Two mixtures are used as eluents: CHCl3/MeOH/AcOH in proportion 89:10:1 
(non-polar solvent) and the same components in proportion 59:40:1 (polar solvent). To visualize 
the TLC results, UV light at 254 nm and a ninhydrin solution are used. 
 Ninhydrin stain solution: a solution of ninhydrin (3.33 g) in absolute EtOH (100 ml). 
The mixture should be kept protected from light. To visualize the TLC, this solution 
is spraying and after heat up a colour change is viewed. 
The separation of amino acids by TLC is based on their polarity. When the solvent ascends 
the stationary phase by capillary action, it drags amino acids. Depending on their polarity, they 
have different affinities for the stationary and mobile phases, ascending the silica gel at different 
rates. This is measured by the Rf value. More polar AA are adsorbed more strongly to the sheet 
(which is relatively polar), and less polar AA ascend the sheet faster because they have more 
affinity for the mobile phase. Therefore, when the sheet is revealed with ninhydrin, the stain 
which is closer to the origin corresponds to the most polar AA [7]. 
 
 
 
 
 
Figure 4. TLC separation of amino acids. 
 
5.2. (H)-(D)-CYS-OH PROTECTION WITH P-NPYS AND BOC 
1.058 g of DTNP (3.4 mmol, 3 eq.) are dissolved in 14 ml of AcOH/DMF (5:95, v/v) at 45 ºC 
for 4 h. When it is completely dissolved, 200 mg (1.1 mmol, 1 eq.) of H-(D)-Cys-OH·HCl·H2O 
are added very slowly (for 6 h) at RT, with stirring and in an inert atmosphere. The mixture is 
stirred overnight at the same conditions, and the end of the reaction is checked by TLC. The 
solution is concentrated in vacuo and to the residue anhydrous Et2O is added, in order to 
precipitate the product and to remove the excess of DTNP and other reaction byproducts. The 
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residue is washed, sonicated and centrifuged with Et2O. Finally Et2O is decanted to obtain the 
product H-(D)-Cys(p-Npys)-OH. 
 
 
 
Brown solid. Yield: 406 mg, 129% (as evidence by TLC, it has not been 
possible to eliminate all DTNP and the byproduct 2-mercapto-5-
nitropyridine). RF = 0.46 (CHCl3/MeOH/AcOH, 59:40:1, v/v), RF = 0.08 
(CHCl3/MeOH/AcOH, 89:10:1, v/v). 
The crude product obtained in the above reaction is dissolved in 5 ml of ACN, and 392 μl of 
DIEA are added to ensure the pH is 8. The mixture is stirred under N2 atmosphere in order to 
avoid the oxidation of cysteine into cystine. Then a solution of 248 mg of Boc2O in 2.2 ml of 
ACN is added. The mixture is stirred for 4 h at 45 ºC, and overnight at RT. After removal of most 
of the ACN in vacuo, the mixture is poured into 10 ml of H2O. Na2CO3 is added until pH is 8. 
Then the mixture is washed with Et2O and acidified to pH 2 with 37% HCl. After that it is 
extracted with AcOEt, and the extracts are washed with water, dried with MgSO4, filtered and 
evaporated again to give the desired crude product, Boc-(D)-Cys(p-Npys)-OH. 
The obtained product was not characterized correctly since, as explained in section 7.2.3., 
it was not pure (as evidence by TLC and HPLC). For that reason it was only characterized by 
ESI mass spectrometry and HPLC. The product was not purified because the final yield would 
be really low. 
 
 
 
 
Yellow oil. Yield: 187 mg, 44%. TLC: RF = 0.92 (CHCl3/MeOH/AcOH, 
59:40:1, v/v), RF = 0.65 (CHCl3/MeOH/AcOH, 89:10:1, v/v). HPLC: tR 
= 28.03 min (lineal gradient from 5% B to 95% B for 30 min, at a flow 
of 1 ml/min; UV detection at 220 nm and 330 nm). Purity: 69%. 
HRMS (ESI+): m/z calc. for C13H17N3O6S2+; 375.7 (41% [M+H]+), 
772.9 (8% [2M+Na]+). HRMS (ESI-): m/z calc. for C13H17N3O6S2-; 
373.6 (58% [M-H]-), 748.8 (99% [2M-H]-). 
 
5.3. SOLID PHASE PEPTIDE SYNTHESIS 
5.3.1. General aspects 
The solid phase peptide synthesis is carried out manually, using polypropylene syringes 
from Terumo (variable volume depending on the quantity of resin used in each case) with a 
porous polyethylene filter from Applied Separations. The reagent mixture is manually stirred 
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using a Teflon wand. After each coupling, the excess of reagents, solvents and other 
byproducts are eliminated by vacuum filtration. 
5.3.2. Loading the resin 
Peptide synthesis is performed using the resin BHA (f = 0.69 mmol/g). The analogs are 
prepared starting from 153.9 mg of resin (0.106 mmol, 1 eq.). Initially is necessary to do a pre-
treatment, because it is stored in a compact form. The objective of this treatment is solvating the 
resin and washing the impurities. The protocol used for the resin BHA is described in table 1: 
Step Reagent Operation Time [min] 
1 DCM* Wash 5 x 0.5 
2 40% TFA/DCM Wash and solvate 1 x 1.0 
3 40% TFA/DCM Wash and solvate 2 x 10 
4 DCM Wash 5 x 0.5 
5 5% DIEA/DCM Neutralization 3 x 2.0 
6 DCM Wash 5 x 0.5 
7 DMF Wash 5 x 0.5 
* DCM used is filtered through a column of silica. 
Table 1. BHA resin loading protocol. 
5.3.3. Synthesis (Fmoc/tBu strategy) 
5.3.3.1. Reference amino acid incorporation 
105 mg of Fmoc-Ala-OH as a reference amino acid (0.318 mmol, 3 eq.), 43 mg of HOBt 
(0.318 mmol, 3 eq.) and 49 μl of DIC (0.318 mmol, 3 eq.) are added to the BHA resin for 60 
min, using anhydrous DMF as solvent. The reference amino acid is useful to do the amino acid 
analysis and to facilitate the solid phase peptide synthesis. The coupling is confirmed by the 
ninhydrin test. If it is incomplete (positive assay, blue beads) a recoupling step is necessary (1.5 
eq. of reagents for 30 min). 
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5.3.3.2. Rink linker incorporation 
To incorporate the Rink linker is necessary to deprotect the reference amino acid removing 
Fmoc, as shows table 2: 
Step Reagent Operation Time [min] 
1 DMF Wash 5 x 0.5 
2 20% piperidine/DMF Deprotection 1 x 1.0 
3 20% piperidine/DMF Deprotection 2 x 10 
4 DMF Wash 5 x 0.5 
Table 2. Fmoc deprotection protocol. 
To the BHA resin with reference amino acid, 172 mg of Fmoc-Rink linker (0.318 mmol, 3 
eq.), 43 mg of HOBt (0.318 mmol, 3 eq.) and 49 μl of DIC (0.318 mmol, 3 eq.) are added, using 
the minimum quantity of anhydrous DMF as solvent. After 60 min, the coupling is tested by the 
ninhydrin assay. If it is positive, a recoupling is necessary with 1.5 eq. of each reagent during 30 
min. 
5.3.3.3. First amino acid incorporation 
First the Rink linker must be treated with a solution of 20% piperidine/DMF (1 x 1 min, 2 x 10 
min), washing the resin with DFM before and after the reaction. Removing of the Fmoc is tested 
by positive result in ninhydrin assay. Then the first amino acid is incorporated, using an excess 
of amino acid: 187 mg (0.318 mmol, 3 eq.) of Fmoc-(D)-Cys(Trt)-OH, 43 mg (0.318 mmol, 3 eq.) 
of HOBt and 49 μl (0.318 mmol, 3 eq.) of DIC in the minimum amount of anhydrous DMF during 
60 min. 
5.3.3.4. Elongation of the peptide chain 
Peptide synthesis is performed manually following standard Fmoc procedures in the 
minimum amount of anhydrous DMF, with DIC as activate agent of the carboxylic acid and 
HOBt as an additive to minimize the racemization of amino acids and to improve the efficiency 
of peptide synthesis. As shown in table 3, every coupling is verified by ninhydrin assay. If the 
test is positive (blue colour), the coupling is repeated from the stage 4, adding 1.5 eq. of the 
reagents for 30 min. When the synthesis is finished, the peptide-resin is washed with DMF and 
DCM and dried in vacuum. 
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Step Reagent Operation Time [min] 
1 DMF Wash 5 x 0.5 
2 20% piperidine/DMF Deprotection 1 x 1.0 
3 20% piperidine/DMF Deprotection 2 x 10 
4 DMF Wash 5 x 0.5 
5 
3 eq. Fmoc-AA-OH* 
3 eq. DIC 
3 eq. HOBt 
Coupling 60 
6 DMF Wash 5 x 0.5 
7 DCM Wash 5 x 0.5 
8 Ninhydrin assay Test coupling 3 
* It refers to: Fmoc-Dab(Boc)-OH, Fmoc-Xxx-OH, Fmoc-(D)-Yyy-OH, Fmoc-Thr(tBu)-OH. 
Table 3. Elongation protocol of peptide chain in Fmoc/tBu synthesis strategy. 
Once the last amino acid is incorporated in the sequence, the Fmoc protecting group is 
removed by treatment with a solution of 20% piperidine/DMF (1 x 1 min, 2 x 10 min). The resin 
is washed with DMF and DCM and divided into three parts for coupling the last amino acid (only 
in analogs 1A and 1B) and the corresponding fatty acid, as shows table 4. 
Analog 
Wet peptidyl-resin 
[mg] 
Equivalent of dry 
resin [mg] 
Last amino 
acid 
Fatty acid 
1A 134.5 45.55 
Fmoc-
Dab(Boc)-OH C6 
1B 156.0 52.83 
Fmoc-
Dab(Boc)-OH C8 
1C 163.9 55.51 
Fmoc-
Thr(tBu)—OH Cx 
Table 4. Last couplings of the three synthesized peptides. 
5.3.3.5. Last amino acid and fatty acid coupling 
In analogs 1A and 1B the last amino acid coupling is carried out following the same 
procedure of the peptide chain elongation (table 3, step 4 – 9). 
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When the peptide sequence is finished, the corresponding fatty acid is coupled in the three 
analogs following the protocol described in table 5. 
Step Reagent Operation Time [min] 
1 DMF Wash 5 x 0.5 
2 20% piperidine/DMF Deprotection 1 x 1.0 
3 20% piperidine/DMF Deprotection 2 x 10 
4 DMF Wash 5 x 0.5 
5 
5 eq. fatty acid 
5 eq. DIC 
5 eq. HOBt 
Coupling 60 
6 
2.5 eq. fatty acid 
2.5 eq. DIC 
2.5 eq. HOBt 
Coupling 30 
7 DMF Wash 5 x 0.5 
8 DCM Wash 5 x 0.5 
9 Ninhydrin assay Test coupling 3 
Table 5. Fatty acid coupling protocol. 
5.3.4. Cleavage from the resin 
When the synthesis is finished, lateral chains of amino acids are deprotected and the 
peptide is cleaved from the resin. This procedure is carried out by acidolysis with 5 ml 
TFA/TIS/H2O (95:3:2, v/v) for 90 min. Then the peptidyl-resin is washed with 95% TFA/H2O. 
TFA is removed by evaporation with N2 stream, and the oily residue obtained is treated with 25 
ml of dry Et2O to obtain the peptide precipitate. The solid peptide is isolated by centrifugation at 
60 r.p.m. for 10 min and the supernatant is poured off. The peptide crude is dissolved in 
H2O/ACN (1:1, v/v), lyophilized and analyzed by analytical HPLC and by ESI mass 
spectrometry. 
 Cleavage yield: analog 1A: 49% (18.07 mg of crude peptide), analog 1B: 62% 
(27.30 mg of crude peptide), analog 1C: 43% (18.51 mg of crude peptide). 
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5.3.5. Cyclization 
The linear peptide is added to a solution of 40 ml of 5% DMSO/H2O (the concentration is 0.5 
mg/ml). The peptide cyclization is carried out in solution to form a disulfide bond between the 
two Cys residues, by an oxidation reaction. It is left to react for 8 h, and controlled by HPLC. 
When the oxidation reaction is finished, the solution is lyophilized. 
 Cyclization yield: analog 1A: 94% (17.00 mg of crude oxidized peptide), analog 
1B: 100% (27.30 mg of crude oxidized peptide), analog 1C: 95% (17.60 mg of 
crude oxidized peptide).  
5.3.6. Purification and characterization 
The crude oxidized peptides are purified by Semipreparative High Performance Liquid 
Chromatography using the following conditions of purification: lineal gradient from 20% of B to 
50% of B for 30 min, at flow of 2 ml/min; UV detection at 220 nm. 
 Purification yield: analog 1A: 38% (6.40 mg of purified peptide), analog 1B: 25% 
(6.80 mg of purified peptide), analog 1C: 19% (3.40 mg of purified peptide). 
The pure fractions are put together and lyophilized, and then the characterization of the 
products is carried out by RP-HPLC and HRMS ESI+.  
Analog Synthesis yield Purity RP-HPLC* (tR) HRMS ESI+* 
1A 18% >99% 27.8 min 
m/z 1176.6 (4% 
[M+H]+), 588.7 (46% 
[(M+2H)/2]2+), 392.7 
(100% 
[(M+3H)/3]3+), 294.6 
(100% [(M+4H)/4]4+) 
1B 16% >99% 33.6 min 
m/z 1204.6 (10% 
[M+H]+), 602.8 (98% 
[(M+2H)/2]2+), 402.1 
(100% [(M+3H)/3]3+) 
1C 8% >99% 33.5 min 
m/z 1119.5 (12% 
[M+H]+), 560.3 
(100% 
[(M+2H)/2]2+), 373.7 
(78% [(M+3H)/3]3+) 
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* RP-HPLC: lineal gradient from 20% of B to 50% of B for 30 min, at flow 1 ml/min; UV detection at 220 nm. The 
chromatograms are shown in appendix 5. HRMS ESI+: spectra are shown in appendix 6. 
Table 6. Final yield and characterization of the synthesized products. 
5.4. CHARACTERIZATION AND PURIFICATION METHODS 
5.4.1. High Performance Liquid Chromatography 
5.4.1.1. Analytical scale 
This technique is used to separate, identify and quantify the components in a mixture. It 
relies on pumps to pass a pressurized liquid solvent containing the sample mixture through a 
column filled with a solid adsorbent material. Each component in the sample interacts slightly 
differently with the adsorbent material, causing different flow rates for the different components 
and leading to the separation of the components as they flow out the column. 
The purity of peptides is assessed using a Nucleosil C18 reverse-phase column (0.4 x 25 
cm) packed with octadecylsiloxane of 5 μm particle diameter and 120 Å pore size, and the 
elution is carried out at 1 ml/min flow with mixtures of 0.045% TFA/H2O (A) and 0.036% 
TFA/ACN (B). Due to that reverse phase has a non-polar stationary phase and an aqueous 
(polar) mobile phase, retention time is longer for molecules which are less polar, while polar 
molecules elute more readily. The UV detection is carried out at 220 nm, because the 
wavelength of absorbance for a peptide bond is 190-230 nm. 
The apparatus used is Shimadzu Serie 20 Prominence which consists of two pumps LC-
20AD model, autosampler SIL-20A, photo-diode Array detector SPD-M20A and System 
Controller CBM-20A. 
5.4.1.2. Semipreparative scale  
This is a technique to isolate and purify compounds from a mixture. The goal is to get the 
single compounds at a certain purity level. It is different from analytical HPLC because of the 
amount of sample applied to the column. In analytical HPLC the applied sample amount is very 
small compared to the amount of stationary phase in the column. Therefore very good 
separations can be achieved. To purify higher amounts of sample in a single run the loadability 
of a column has to be increased [14]. 
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Peptides are purified by preparative HPLC using a Phenomenex® C18 column (25 x 1 cm, 5 
μm diameter). Elution is carried out at 2 ml/min flow with 0.1% TFA/H2O (A) and 0.1% TFA/ACN 
(B), and UV detection at 220 nm. The apparatus used is a Waters Delta Prep 3000 (Preparative 
Chromatography System) which consists of a controller and a pump Waters 600 E model, a 
manual sample injector Waters 712, a detector of variable wavelength Waters 484 and a chart 
recorder Pharmacia Biotech REC 101.  
5.4.2. Electrospray Ionization Mass Spectrometry 
ESI is a technique used in mass spectrometry to produce ions using an electrospray in 
which a high voltage is applied to a liquid to create an aerosol. It is a soft ionization technique 
typically used to determine the molecular weights of proteins, peptides and other biological 
macromolecules. It is useful because its process does not fragment the macromolecules into 
smaller charged particles; rather it turns the macromolecule being ionized into small droplets. 
These droplets will then be further desolvated into even smaller droplets, which creates 
molecules with attached protons. These protonated and desolvated molecular ions will then be 
passed through the mass analyzer to the detector, and the mass of the sample can be 
determined.  
This quantitative analysis is done by considering the mass to charge ratios of the various 
peaks in the spectrum. This spectrum shows the m/z ratio on the x-axis and the relative intensity 
(%) on the y-axis. In positive mode, the ions observed are created by the addition of a hydrogen 
cation (denoted [M+H]+), or of another cation such as sodium ([M+Na]+) or potassium ([M+K]+). 
In addition, multiply charged ions such as [M+nH]n+ are often observed [15,16]. 
The samples analyzed are solutions of peptides in H2O/ACN (1:1 v/v), and mass spectra are 
obtained in positive mode using the spectrometer ZQ-Micromass (Waters). 
5.5. EVALUATION OF ANTIMICROBIAL ACTIVITY 
5.5.1. Preparation of material and medium 
Material and growth medium of bacteria must be sterilized to ensure the elimination of any 
form of life. Pipette tips, glass bottles, flasks and MilliQ-water are autoclaved (subjecting them to 
high pressure saturated steam at 121ºC for 15-20 min). 
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Different culture mediums are prepared and also autoclaved: 1 x concentrated MHB (9.6 g 
in 400 ml MilliQ-water), 2 x concentrated MHB (19.4 g in 400 ml MilliQ-water) and 1 x 
concentrated MHB with Agar (6g) for plates. 
5.5.2. Growth and inoculation of bacteria 
The microorganisms used are: 
 Gram-negative bacteria: Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 9027. 
 Gram-positive bacteria: Enterococcus faecalis ATCC 29212, Staphylococcus 
aureus ATCC 29213. 
Four bacteria suspensions are prepared following the protocol of Amsterdam, D. [17,18]. 50 
μL of each suspension in MHB adjusted according to McFarland standard is added to the 
microtiter wells, so the final concentration of each bacterium in every well is 106 UFC/ml. 
5.5.3. Preparation of peptides solutions 
About 1 mg of each peptide is needed to prepare the solutions in MilliQ-water. The starting 
concentration of microplates for MIC testing is 128 μg/ml, so the wished concentration of 
peptide solutions is 512 μg/ml (128x4). 
Peptide Weight [mg] Real weight* [mg] 
Volume of MilliQ-
water [μl] 
1A 1.1 0.77 1504 
1B 0.9 0.63 1230 
1C 1.0 0.70 1367 
PxB 0.9 0.76 1494 
*Real weight of the synthesized peptides is 70% of their total weight, because they contain the counterion 
CF3COO- from TFA. Real weight of PxB is 86% of its total weight, because commercial product contains 2·H2SO4. 
Table 7. Peptides solutions for the MIC test. 
5.5.4. Determination of MIC 
To carry on MIC test four microtitres of 96 wells are needed (8 rows x 12 columns, figure 5). 
In each microplate one peptide will be analyzed (PxB and the three synthesized analogs). 
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 50 μl of 2xMHB are added to column 1. 
 50 μl of 1xMHB are added to columns 2-11. 
 100 μl of 1xMHB are added to column 12. 
 50 μl of peptide solution are added to column 1. With a multichannel pipette, the 
mixture in column 1 is stirred and 50 μl are added to column 2. The mixture in 2 is 
also stirred and 50 μl are added to column 3. Thus successively through column 
10, so we get peptide concentration diluted by half. So that the final 
concentrations of the peptides ranging from 28 μg/ml (column 1) to 0.25 μg/ml 
(column 10). 
 Finally, the four bacterial suspensions are added to microtitres. Each bacterium 
only takes two rows. Microplates are incubated at 37 ºC for 20 – 22 h. 
 Column 11 is the positive control. It only contains 50 μl of bacteria and 50 μl of 
medium, so we can ensure the growth of bacteria without peptide solution. 
 Column 12 is the negative control. It only contains MHB growth medium, so we 
can ensure there is no bacteria growth because the medium is sterilized. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Preparation of the microplates for the MIC test. 
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6. (D)-CYS PROTECTION 
One of the objectives of this present work was to find an effective method to synthesize the 
compound Boc-(D)-Cys(p-Npys)-OH, since, as explained later, the compound para-nitro-2-
pyridinesulfenyl (p-Npys) has certain advantages over other protecting groups. 
6.1. P-NPYS AS AN ACTIVATING AND PROTECTING GROUP 
To form an asymmetric disulfide bond between two lateral chains of cysteine, the activation 
of the thiol function of one of the AA is required, followed by the addition of the second AA in the 
free thiol form. One of the most successful and widely used method employs aromatic sulfenyl 
protecting/activating groups, such as Nps, PyrS and Npys. The formation of the disulfide bond is 
driven by the low pKa of the aromatic thiol, and hence the reaction can be performed under 
acidic conditions. However, the Npys and other activated Cys derivatives are not compatible 
with the Fmoc/tBu strategy, as they are not stable to the strongly basic conditions required for 
the removal of the Fmoc group. Consequently, the activation of Cys in peptides assembled by 
Fmoc/tBu strategy is often performed with Npys-Cl, but sulfenyl chlorides have limited stability 
and can react with other groups. 
 
 
 
Figure 6. Protecting groups Npys and p-Npys, and reagent DTNP. 
The Npys group (9) not only acts protecting the thiol function of Cys, but also the Npys-
modified cysteine can react selectively with the free thiol group of another cysteine molecule to 
afford a new disulfide bond. This group is easily removed under neutral conditions using tertiary 
phosphine and water, by a reduction reaction, but it is sufficiently resistant to acids such as 
TFA, HCl and HF. 
The use of 2,2’-dithiobis(5-nitropyridine) or DTNP (11) as an activating reagent for the thiol 
function of cysteine generates the protecting/activating group p-Npys (10), which is an isomer of 
Npys. This compound facilitates the synthesis and increases the acidity of the thiol because of 
the para nitro group, making it a better leaving group than Npys [19,20]. 
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6.2. BOC PROTECTING GROUP 
Boc protecting groups are used to temporarily protect the N-alpha nitrogen groups of the 
amino acids. This group is usually used in a Boc/BzI synthesis strategy, which is not a true 
orthogonal protection scheme, because both groups are acid labile [8]. 
Boc group is orthogonal to p-Npys group, because they are removable under completely 
different conditions. While Boc is removed under moderate acid conditions (50% TFA/DCM), p-
Npys requires reduction conditions (DTT, tertiary phosphine). In addition, Boc group can be 
introduced with the reagent Boc2O to a p-Npys-protected AA, because this reaction requires 
medium basic conditions (pH 8) as shows figure 7.  
 
 
 
 
 
 
Figure 7. Reaction mechanism of Boc protection, in a nucleophilic substitution of an acyl group where a 
carbamate (Boc protected amino acid) is formed. 
6.3. SYNTHESIS AND CHARACTERIZATION OF BOC-(D)-CYS(P-NPYS)-OH 
As explained in section 5.2.2., the lateral chain of H-(D)-Cys-OH (12) was initially protected 
with the group p-Npys. The amino acid was added very slowly to a solution of DTNP to ensure 
the no-formation of a dimer of cysteine (cystine) in an oxidation reaction. For the same reason 
the reaction took place in an inert atmosphere, without oxygen. The reaction was followed by 
TLC, using a relatively polar mobile phase formed by CHCl3/MeOH/AcOH in proportion 59:40:1, 
v/v. The final product obtained was a brown solid formed by the synthesized p-Npys-AA (13) 
and for a small part of the non-reacted AA, the excess of DTNP and the byproduct 2-mercapto-
5-nitropyridine (14), which could not be removed, as evidence by TLC (figure 8, 9). 
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Figure 8. Synthesis of Boc-(D)-Cys(p-Npys)-OH. 
 
 
 
 
 
 
Figure 9. TLC sheet where (a) corresponds to DTNP and (b) to the synthesized product H-(D)-
Cys(pNpys)-OH. All stains were revealed in UV light at 254 nm. The AA and the synthesized product were 
revealed with ninhydrin and without heating, since they contain a primary amine. The 
mercaptonitropyridine was recognized by its yellow color, and commercial DTNP was used as a standard. 
In a second part of the synthesis, the N alpha group of H-(D)-Cys(p-Npys)-OH (13, figure 8) 
was protected with the Boc group, with the reagent Boc2O in a nucleophilic substitution reaction, 
using DIEA as a base. The reaction took place in an inert atmosphere and was followed by TLC, 
using a relatively non-polar mobile phase formed by CHCl3/MeOH/AcOH in proportion 89:10:1, 
v/v. Figure 10 shows the TLC sheet when the reaction was completed and the product Boc-(D)-
Cys(p-Npys)-OH (15, figure 8) was obtained. 
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Figure 10. TLC sheet where (a) corresponds to the commercial product Boc-(D)-Cys(pNpys)-OH, (b) to 
DTNP and (c) to the synthesized product Boc-(D)-Cys(pNpys)-OH. All stains were revealed in UV light at 
254 nm, excepting the Boc-(D)-Cys-OH stain. The synthesized product was revealed with ninhydrin, HCl 
vapors and heating. Nitropyridine was recognized by its yellow color, and commercial DTNP was used as 
a standard. 
Boc group is not visible with UV light at 254 nm, because it does not absorb at this λ. 
Moreover, N-alpha protected amino acids cannot be revealed with ninhydrin because their 
amine groups are not free. Therefore, to reveal the stains of compounds which have Boc group 
it’s necessary to apply HCl vapors and to heat, in order to deprotect them. The mechanism of 
this reaction is showed in figure 11. 
 
 
 
 
 
 
 
Figure 11. Boc deprotection mechanism in an acidic hydrolysis with HCl. 
Finally, the work up of the product was made by extractions. Initially water was added and 
the product was washed with diethyl ether. Thus the initial reagents DTNP and Boc2O and the 
byproduct 2-mercapto-5-nitropyridine stayed in the organic phase, as evidence by TLC. The 
aqueous phase was acidified with HCl and extracted with AcOEt. The free AA and the Boc-
protected AA stayed in the aqueous phase, while the synthesized product moved to the organic 
phase. AcOEt was evaporated, dried and filtered to obtain the product Boc-(D)-Cys(p-Npys)-
OH. 
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As shows TLC sheet (CHCl3/MeOH/AcOH in proportion 89:10:1, v/v, figure 12) the obtained 
product was not pure, and that is why a good characterization was not made. The product 
synthesized with a yield of 44% was characterized by ESI mass spectrometry and HPLC, and it 
was not purified because the yield would be very low. 
 
 
 
 
 
Figure 12. TLC sheet where (a) corresponds to the diethyl ether phase, (b) to the aqueous phase and (c) 
to the AcOEt phase. The byproduct in phase (c) could not be determined; therefore the desired product 
was not purified. 
7. SYNTHESIS OF POLYMYXIN ANALOGS 
7.1. DESIGN 
The main objective of this present work was to obtain analogs of PxB which conserve or 
improve its efficiency against gram-negative microorganisms, or that expand its range of action, 
being active against gram-positive microorganisms and, if possible, reducing the toxicity of PxB. 
As shows figure 13, the differences between PxB and the synthesized analogs are: 
 Substitution of the amide bond between residues Dab-4 and Thr-10, which forms 
the cyclic heptapeptide, for a disulfure bridge between the residues that are in the 
same position, Cys-4 and (D)-Cys-10. This modification keeps the size of the 
cycle and simplifies the synthetic process. 
 Substitution of the residues 6 and 7, which represent the hydrophobic part of the 
cycle, for the amino acids Xxx and (D)-Yyy. These residues cannot be public for 
reasons of confidentiality.  
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 Variation of the acid (S)-6-methyloctanoic for different fatty acids in analogs 1A 
and 1B, and substitution of Dab-1 for the fatty acid Cx in analog 1C. These 
modifications, along with substitution of residues 6 and 7, vary the hydrophobicity 
of the molecule. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* In analog 1C the AA 1-Dab is substituted for the fatty acid Cx. 
Figure 13. Comparison between PxB and the synthesized analogs. 
The sequence of the synthesized peptides is shown in table 8: 
Peptide Sequence 
1A Hexanoyl-Dab-Thr-Dab-cyclo-[Cys-Dab-(D)-Yyy*-Xxx*-Dab-Dab-(D)-Cys] 
1B Octanoyl-Dab-Thr-Dab-cyclo-[Cys-Dab-(D)-Yyy*-Xxx*-Dab-Dab-(D)-Cys] 
1C Cx*-Thr-Dab-cyclo-[Cys-Dab-(D)-Yyy*-Xxx*-Dab-Dab-(D)-Cys] 
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*Xxx = NH2CH(R1)COOH; Yyy = NH2CH(R2)COOH; Cx = (R3)COOH. Amino acids and fatty acid structure can’t be 
disclosed for reasons of confidentiality 
Table 8. Sequences of the synthesized PxB analogs. 
7.2. SYNTHESIS 
7.2.1. Synthesis strategy 
The analogs of polymyxin were synthesized following the Fmoc/tBu protection strategy. In 
this protection scheme, the alpha nitrogen of the amino acids is protected with the base labile 
Fmoc group, while the side chains are protected with acid labile groups based either on the tert-
butyl protecting group or the trityl (triphenylmethyl) group. This is an orthogonal protection 
system, since the side chain protecting groups can be removed without displacing de N-terminal 
protection and visa versa. It is advantageous when side chains need to be selectively modified, 
as when the peptide is selectively labeled or cyclized through the side chain [8]. 
The solid phase peptide synthesis was carried manually and performed using the resin 
BHA, which had to be pre-treated as explains section 5.3.2. 
Initially, Fmoc-Ala-OH was coupled to the resin BHA as a reference amino acid, facilitating 
the SPPS because it avoids steric and electronic problems. The reaction was carried out using 
DIC and HOBt, for 1 hour in anhydrous DMF. 
 
 
 
 
 
 
 
 
Figure 14. Coupling of the first amino acid to the resin BHA. 
 
Carbodiimides are commonly used to prepare amides, esters and acid anhydrides from 
carboxylic acids, so diisopropylcarbodiimide (DIC) was used as an activate agent of the 
carboxylic acid of the amino acid. This reagent and its urea byproduct are more water soluble, 
so the byproduct and any excess reagent are removed by aqueous extraction. Carbodiimide 
activation of AA derivatives often causes a partial racemization of the AA, so in peptide 
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synthesis, adding an equivalent of 1-hydroxybenzotriazole (HOBt) minimizes this problem, 
improving the efficiency of the SPPS [8]. The mechanism of this coupling is shown in figure 15. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Activation of the AA. The attack of HOBt is based on a reaction of addition-elimination. 
After this coupling, the Fmoc group of the reference amino acid was removed with a solution 
of 20% of piperidine in DMF, as is explained in section 5.3.3.2. (table 2). The Fmoc group is 
removed when a base abstracts the relatively acidic proton from the fluorenyl ring system, 
leading to a β-elimination and the formation of dibenzofulvene and carbon dioxide, as shows 
figure 16. Dibenzofulvene is a reactive electrophile and would readily attach irreversibly to the 
deprotected amine unless it was scavenged. Secondary amines such as piperidine add to 
dibenzofulvene and prevent deleterious side reactions. Hence piperidine is typically used to 
remove the Fmoc group and also scavenge the dibenzofulvene by-product. 
After Fmoc removal, Fmoc-Rink linker was coupled to the reference amino acid, following 
the procedure shown in section 5.3.3.2. Linkers are chemical entities used to ―link‖ a compound 
to a resin bead during SPPS. The nature of the linker determines the kind of chemistry that can 
be performed, and the conditions under which products can be cleaved from the resin [8]. The 
RL used was a benzhydrylamine functionalized with two methoxy groups at ortho and para 
positions. This enables the cleavage of the peptide-RL bond with a solution of TFA in H2O, and 
obtaining the peptide with the C-terminal end in carboxamide form. 
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Figure 16. Fmoc deprotection mechanism. 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Rink linker incorporation to the peptidyl-resin. 
For the elongation of the peptide chain, each AA coupling was carried out with 3 eq. of 
Fmoc-AA-OH, 3 eq. of DIC and 3 eq. of HOBt in anhydrous DMF for 1 h. The efficiency of the 
reactions was controlled by ninhydrin test (section 5.1.3.1.).  
As explained above, lateral chains of AA were protected with acid labile groups. The 
protecting group of the lateral chain of Cys residues was Trt, in order to obtain a fully 
deprotected linear precursor after the cleavage from the resin, and allowing the disulfide bond 
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formation in aqueous solution by oxidation. Regarding other trifunctional amino acids, Dab was 
protected with Boc group and Thr was protected with tBu group. 
Once the last amino acid was incorporated in the sequence, fatty acids were coupled in the 
three analogs following the protocol described in section 5.3.3.5. 
 
 
 
 
 
 
 
 
 
Figure 18. Formation of the linear peptidyl-resin with Fmoc/tBu SPPS. 
Then the cleavage of the peptide from the resin and de removing of the lateral chains 
protecting groups were carried out by acidolysis, with a treatment of TFA/TIS/H2O (95:3:2, v/v). 
Triisopropylsilane (TIS) function is to reduce carbocations. 
So finally, totally unprotected linear precursors were obtained. 
7.2.2. Cyclization 
The cyclization of the synthesized peptides was performed by oxidation of the thiol groups 
of Cys residues to form a disulfide bond, as shows figure 19. Lineal peptides were added to a 
solution of 5% DMSO/H2O, therefore its concentration was 0.5 mg/ml. Under conditions of high 
dilution formation of cyclic dimers and oligomers is avoided. 
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Figure 19. Cyclization by an oxidation reaction of the linear peptides to form the definitely analogs. 
The oxidation reaction was followed by RP-HPLC. The peptides were cyclisized after 8 h. 
 
 
   
t = 1 h     t = 8 h 
Figure 20. Oxidation process of the analog 1B. At t=1h the percentage of the cyclic peptide was 44%, 
and after 7 hours it increased to 95%. The samples were analyzed with a lineal gradient from 20% to 50% 
of B for 30 min. (Solution A: 0.045% TFA/H20, solution B: 0.036% TFA/ACN; UV detection at λ 220 nm). 
In all cases a fast disappearance of the chromatographic peak of the linear peptide and the 
subsequent emergence of a new peak corresponding to the cyclic peptide is observed. 
Cyclization yields were 94 – 100%; therefore it is an optimal methodology for a complete 
peptide cyclization. 
Finally the solutions were lyophilized to obtain the crude oxidized peptides. 
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7.2.3. Purification and characterization 
The crude peptides obtained after cyclization were purified by RP-HPLC in a 
semipreparative scale. Final peptides were obtained with good purities (>99%), as is shown in 
RP-HPLC and ESI spectra (appendices 5, 6). The yields are shown in table 9: 
Peptide ɳ cleavage ɳ cyclization ɳ purification ɳ synthesis 
1A 49% 94% 38% 18% 
1B 62% 100% 25% 16% 
1C 43% 95% 19% 8% 
Table 9. Cleavage, cyclization, purification and final yields of the synthesized analogs. 
The cleavage yield was calculated from the weight of crude peptide after TFA treatment, 
using as a theoretical value the calculated from the initial dry resin and its functionalization. The 
cyclization yield was calculated from the weight of peptide obtained after cyclization and the 
weight obtained after TFA treatment. The purification yield was obtained from the weight of the 
final pure peptide and the weight of the cyclic peptide. Finally, the total yield was expressed as a 
combination of the cleavage, cyclization and purification yields. 
Synthesis yields are quite low, especially in analog 1C. Due to it was the first time these 
peptides were synthesized, it was necessary to make a large number of mini-cleavages in order 
to control if the chains were elongating correctly.  
8. DETERMINATION OF MINIMUM INHIBITORY 
CONCENTRATION 
8.1. GENERAL ASPECTS 
One of the main objectives of this present work was to determinate the antimicrobial activity 
of the synthesized peptides.  
This activity is expressed with minimum inhibitory concentrations, which are defined as the 
lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism 
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after overnight incubation. MICs are used by diagnostic laboratories mainly to confirm 
resistance, but most often as a research tool to determinate the in vitro activity of new 
antimicrobials [21]. 
The MIC of the synthesized PxB analogs was determined following the protocol described 
for Amsterdam, D. [17,18]. As explained in section 5.5, four bacteria suspension were prepared 
(with a concentration of 106 UFC/ml). A stock solution of each peptide in MilliQ-water was also 
prepared, from which we obtained a range of concentrations from 0.25 μg/ml to 128 μg/ml. 
Peptides and bacteria were incubated with the growth medium MHB at 37 ºC for 20 – 22 h. 
8.2. BACTERIA 
To carry on these assays the microorganisms used were: 
 Gram-negative bacteria: Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 9027. 
 Gram-positive bacteria: Enterococcus faecalis ATCC 29212, Staphylococcus 
aureus ATCC 29213. 
In the following section there is a brief description of these bacteria [22]: 
8.2.1. Gram-negative bacteria 
 Escherichia coli is the typical standard model of gram-negative bacteria. It is a rod-
shaped bacterium that is commonly found in the lower intestine of warm-blooded 
organisms. Most E. coli strains are harmless. These strains are part of the normal 
flora of the gut, and can benefit their hosts by producing vitamin K and preventing 
colonization of the intestine with pathogenic bacteria. But there are also harmful 
strains which can cause many excretory system infections, such as cystitis, urethritis, 
meningitis, mastitis, pneumonia… In recent years the resistance of this bacterium to 
antibiotics has increased. 
 Pseudomonas aeruginosa is a model of gram-negative resistant bacteria. It is a 
pathogen microorganism which can cause chronic infections, and has a low 
susceptibility to antibiotics. It may cause pneumonia, excretory system infections… 
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Because it thrives on moist surfaces, this bacterium is also found on and in medical 
equipment, so can cause cross-infections in hospitals and clinics. 
8.2.2. Gram-positive bacteria 
 Staphylococcus aureus is at present the main cause of nosocomial infections. This is 
favored by the fact that it is found in the skin and mucous membranes of humans, 
allowing through surgical wounds can enter the patient’s bloodstream. This bacterium 
can produce a wide range of diseases, ranging from skin infections and relatively 
benign, such as folliculitis, until disease life-threatening, such as osteomyelitis, 
meningitis, sepsis, endocarditis and pneumonia. Resistant strains of this bacterium 
are resistant to penicillin, and they are treated with aminoglycosides or oxacillin. 
 Enterococcus faecalis is found in the intestine of humans and other warm-blooded 
organisms. It indicates fecal contamination, so its present in foods indicates poor 
hygiene or poor conservation, but it is also present on some foods like cheese, where 
acts as natural bacteria flora. It may be resistant to all antibiotics in use. 
8.3. RESULTS AND DISCUSSION 
After overnight incubation, MIC of the synthesized peptides was determined visually using 
an amplifier. Polymyxin B (PxB) was used as a standard. 
The results of this qualitative test are shown in table 10.  
                     Peptides 
           Bacteria                                    
MIC [μg/ml] 
PxB 1A 1B 1C 
Gram - 
E. coli <0.25 2 – 4 2 2 
P. aeruginosa <0.25 <0.25 <0.25 0.25 
Gram + 
S. aureus 32 32 4 4 
E. faecalis >128 >128 16 – 32 64 – 128 
Table 10. MIC results for PxB and the three synthesized analogs. 
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The results of MIC test show that the analog 1B presents the best antimicrobial activity. In 
addition of being effective against gram negative bacteria, has a good selectivity against gram 
positive bacteria, actually better than polymyxin. Therefore, comparing with the analog 1A 
(which does not improve the effectiveness of PxB), it can be concluded that the 8C fatty acid 
chain has provided more antibacterial activity than the 6C chain. The analog 1C also shows a 
good effectiveness against gram positive bacteria, especially into the bacterium S. Aureus. 
9. CONCLUSIONS 
The final conclusions of this present work are: 
 The synthesis methodology using the solid phase peptide synthesis, the resin 
BHA and the Fmoc/tBu strategy allows obtaining the desired peptides with high 
purities (>99%). Although synthesis yields have not been very high, it is a simple 
and effective methodology. 
 The determination of minimum inhibitory concentration (MIC) of the synthesized 
analogs has led to good results, with high selectivity against gram negative 
bacteria and acceptable activity against gram positive bacteria. MIC values are 
comparable and even better, in some cases, than polymyxin B. The best obtained 
results correspond to the analog 1B, which has a residue of Dab in position 10 
and a fatty acid of eight carbons. 
 The synthesis of the protected amino acid Boc-(D)-Cys(p-Npys)-OH has not been 
successful, due to the low purity of the crude compound obtained and the 
expected low yield after purification. 
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11. ACRONYMS 
AA   Amino acid 
ACN   Acetonitrile 
ADEPs  Acyldepsipeptides 
AMPs  Antimicrobial peptides 
ATCC  American Type Culture Collection 
BHA   Benzhydrylamine resin 
Boc   tert-butyloxycarbonyl 
tBu   tert-butyl 
DCM   Dichloromethane 
DIEA   N,N-Diisopropylethylamine 
DIC   N,N’-Diisopropylcarbodiimide 
DMF   N,N’-Dimethylformamide 
DMSO  Dimethyl sulfoxide 
DTNP  2,2’-Dithiobis(5-nitropyridine) 
Eq.   Equivalents 
f   Functionality 
Fmoc  Fluorenylmethyloxycarbonyl 
HOBt   1-Hydroxybenzotriazole 
HPLC  High Pressure Liquid Chromatography 
m/z   Mass-to-charge ratio 
MHB   Mueller Hinton-Broth (culture media) 
MIC   Minimum inhibitory concentration 
Min   Minutes 
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Nps   3-nitrophenyl 
Npys   3-nitro-2-pyridinesulfenyl 
Npys-Cl  3-nitro-2-pyridinesulfenyl chloride 
p-Npys  5-nitro-2-pyridinesulfenyl 
PxB   Polymyxin B 
PyrS   2-pyridinesulfenyl 
RL   Rink linker 
r.p.m.  Revolutions per minute 
SPPS  Solid phase peptide synthesis 
TFA   Trifluoroacetic acid 
TIS   Triisopropylsilane 
TLC   Thin layer chromatography 
Trt   Triphenylmethyl (trityl) 
UFC   Colony-forming unit 
UV   Ultraviolet 
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APPENDICES 
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APPENDIX 1: SYNTHESIZED ANALOGS STRUCTURE 
 
Name Structure 
1A 
 
 
 
1B 
 
1C 
 
*Xxx = NH2CH(R1)COOH; Yyy = NH2CH(R2)COOH; Cx = R3COOH. Amino acids and fatty acid structure can’t be 
public for reasons of confidentiality
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APPENDIX 2: AMINO ACIDS USED 
 
Amino acid Type Structure 
 
C 
Cysteine 
(Cys) 
 
 
Proteinogenic 
 
 
L-(2,4)-Diaminobutyric acid 
(Dab) 
 
Non-proteinogenic 
 
 
T 
Threonine 
(Thr) 
Proteinogenic 
 
APPENDIX 3: COUPLING AGENTS AND ADDITIVES 
 
Abbreviation Name Structure 
 
DIC 
 
N,N’-Diisopropylcarbodiimide 
 
 
HOBt 
 
1-Hydroxybenzotriazole 
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APPENDIX 4: PROTECTING GROUPS 
 
Abbreviation Name Structure Lability 
 
Boc 
 
Tert-butyloxycarbonyl 
 
TFA 
 
tBu 
 
Tert-butyl  TFA 
 
 
Fmoc 
 
 
 
Fluorenylmethyloxycarbonyl 
 
Piperidine 
 
p-Npys 
 
 
para-5-nitro-2-
pyridinesulfenyl 
 
Tertiary phosphine, 
DTT 
 
 
 
Trt 
 
 
 
Triphenylmethyl (trityl) 
 
TFA 
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APPENDIX 5: CHROMATOGRAMS OF PURE PEPTIDES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. HPLC chromatograms of pure peptides: 1A, 1B and 1C. Lineal gradient from 20% to 50% for 
30 min; UV detection at 220 nm.
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APPENDIX 6: ESI SPECTRA OF PURE PEPTIDES 
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Figure 22. ESI-HRMS spectra of pure peptides: 1A, 1B and 1C. 
